AI Article Synopsis
- Temsirolimus showed unexpectedly high effectiveness as a third-line treatment for a patient with metastatic chromophobe renal cell carcinoma, following the failure of two previous tyrosine kinase inhibitors.
- The patient experienced a prolonged partial remission lasting 14 months, and this positive response is ongoing.
- This case suggests that temsirolimus could be a promising alternative treatment option for similar patients, despite the lack of prior clinical study data on its use in this context.
Article Abstract
We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082484 | PMC |
| http://dx.doi.org/10.1159/000323804 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!